or their pharmaceutically acceptable salts wherein R1, R2, R3 and R4 are presented in the description and exhibit substantial COMT inhobotory activity. Besides, the present invention described pharmaceutical compositions inhibiting catechol-O-transferase activity which contain the compound or its pharmaceutically acceptable salt as an active ingredient, and a pharmaceutically acceptable carrier.;EFFECT: there are declared pharmaceutical combinations for treatment or prevention of Parkinson's disease which contain (1) the pharmaceutical composition containing the compound under any cl 1-8 or its pharmaceutically acceptable salt and the pharmaceutically acceptable carrier, and (2) at least one compound specified in L-dope or carbidole.;10 cl, 9 ex, 17 tbl"/> NEW CATECHIN DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING CATECHIN DERIVATIVE, USING CATECHIN DERIVATIVE AND USING PHARMACEUTICAL COMPOSITION
首页> 外国专利> NEW CATECHIN DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING CATECHIN DERIVATIVE, USING CATECHIN DERIVATIVE AND USING PHARMACEUTICAL COMPOSITION

NEW CATECHIN DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING CATECHIN DERIVATIVE, USING CATECHIN DERIVATIVE AND USING PHARMACEUTICAL COMPOSITION

机译:包含儿茶素衍生物的新型儿茶素衍生物,药物组合物,其使用儿茶素衍生物和药物组合物

摘要

FIELD: medicine, pharmaceutics.;SUBSTANCE: present invention offers compounds presented by general formula (I): or their pharmaceutically acceptable salts wherein R1, R2, R3 and R4 are presented in the description and exhibit substantial COMT inhobotory activity. Besides, the present invention described pharmaceutical compositions inhibiting catechol-O-transferase activity which contain the compound or its pharmaceutically acceptable salt as an active ingredient, and a pharmaceutically acceptable carrier.;EFFECT: there are declared pharmaceutical combinations for treatment or prevention of Parkinson's disease which contain (1) the pharmaceutical composition containing the compound under any cl 1-8 or its pharmaceutically acceptable salt and the pharmaceutically acceptable carrier, and (2) at least one compound specified in L-dope or carbidole.;10 cl, 9 ex, 17 tbl
机译:技术领域:本发明提供由通式(I)表示的化合物:<图像文件=“ 00000069.GIF” he =“ 36” imgContent =“ undefined” imgFormat =“ GIF” wi =“ 104” />或其药学上可接受的盐,其中R 1 ,R 2 ,R 3 和R 4 描述并展示大量的COMT策划活动。此外,本发明描述了抑制儿茶酚-O-转移酶活性的药物组合物,其含有该化合物或其药学上可接受的盐作为活性成分,以及药学上可接受的载体。效果:已宣布用于治疗或预防帕金森氏病的药物组合(1)药物组合物,其包含(1)含有任何cl 1-8下的化合物或其药学上可接受的盐和药学上可接受的载体,以及(2)至少一种在L-浓液或卡比多尔中指定的化合物。; 10 cl,9 ex ,17汤匙

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号